Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Intercept Pharma (ICPT) Prices Aggregate $400M Conv. Notes Offering
June 30, 2016 9:18 AM EDTIntercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes). Intercept has granted the underwriters an option, exercisable for 30 days, to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments. The offering is expected to close on or about July 6, 2016, subject to customary closing conditions.
The notes will be senior unsecured obligations of Intercept. The notes will bear interest at a rate of 3.25% per... More



